MULTICENTER NETWORK OF NEONATAL INTENSIVE CARE UNITS

我们要求继续参加NICHD新生儿合作组织 中国互联网.我们的主要优势包括： （1）患者群体庞大。1994年，我们有16 742名新生儿，291名极低出生体重儿， 婴儿和1450名新生儿ICU入院（97%为先天性）。充分和有效 我们的婴儿参与网络试验是由我们的 教师的保守治疗理念。 2)一个高素质的私家侦探。泰森博士在以下方面拥有丰富的经验： 多中心试验，在实验设计方面的不寻常的专业知识， 对卫生政策、卫生保健方面的“前沿”问题的不寻常的了解 经济学和成果研究。他不仅是儿科教授 和产科在UT西南达拉斯，但也兼职教授 他在休斯顿公共卫生学院的流行病学研究 1993-1994年，卫生政策研究所客座教授。 3)在网络上有很好的记录。我们在这两个方面都排名靠前 符合条件的婴儿入学率和占网络总入学率的百分比 过去10年的研究。我们的PI做出了巨大贡献， 设计了下一个重大试验，一个将持续大约16年的试验， 两个月，两个融资周期。在下一个融资周期，他 已建议进行一项获督导委员会通过的大型试验， 婴儿的资源使用、创伤、辐射和医院感染 等于或小于1000 g BW。 4)其他主要优势。 这些措施包括：a）高生产力的新生儿 B）一个围产期合作者谁是相当有经验的大 管理试验和PI在围产期网络中的应用; （c）一个广泛和组织良好的新生儿数据库， d）一个后续诊所，不仅在以下方面表现出色： 观察性研究以及后续干预的主要试验， 例如初级保健试验（由卫生保健政策局资助） 婴儿健康和发展计划（由 NICHD和Robert Wood约翰逊基金会）。

We request continued participation in the NICHD Cooperative Neonatal Research Network. Our major strengths include: l) A large patient population. In 1994 we had 16,742 births, 291 VLBW infants, and 1450 neonatal ICU admissions (97% inborn). Full and effective participation of our infants in Network trials is fostered by our faculty's conservative treatment philosophy. 2) A highly qualified PI. Dr. Tyson has extensive experience in multicenter trials, unusual expertise in experimental design, and an uncommon knowledge of "cutting edge" issues in health policy, health care economics, and outcomes research. He is not only Professor of Pediatrics and Obstetrics at UT Southwestern in Dallas but also Adjunct Professor of Epidemiology at the School of Public Health in Houston where he was Visiting Professor at the Health Policy Institute during 1993-1994. 3) A strong track record in the Network. We have ranked high in both percent of eligible infants enrolled and in total enrollment in Network studies during the past 10 years. Our PI has contributed heavily and has designed the next major trial, a trial that will last approximately 16 months and bridge the 2 funding periods. For the next funding period, he has proposed a major trial endorsed by the Steering Committee to reduce resource use, trauma, radiation, and nosocomial infection among infants equal to or less than 1000 g BW. 4) Other major strengths. These include a) a highly productive neonatal division; b) a perinatal collaborator who is quite experienced in large management trials and the PI in an application to the Perinatal Network; c) an extensive and well organized neonatal data base of proven value to the Network; and d) a follow-up clinic that has excelled in not only observational studies but also major trials of follow-up interventions, e.g. the Primary Care Trial (funded by the Agency for Health Care Policy and Research) and the Infant Health and Development Program (funded by NICHD and the Robert Wood Johnson Foundation).